These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 25870084)
21. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Senda M; Ogawa S; Nako K; Okamura M; Sakamoto T; Ito S Endocr J; 2012; 59(10):889-94. PubMed ID: 22785236 [TBL] [Abstract][Full Text] [Related]
22. CCK, ghrelin, and PYY responses in individuals with binge eating disorder before and after a cognitive behavioral treatment (CBT). Munsch S; Biedert E; Meyer AH; Herpertz S; Beglinger C Physiol Behav; 2009 Apr; 97(1):14-20. PubMed ID: 19419677 [TBL] [Abstract][Full Text] [Related]
23. The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat. Hansen HH; Hansen G; Paulsen S; Vrang N; Mark M; Jelsing J; Klein T Eur J Pharmacol; 2014 Oct; 741():254-63. PubMed ID: 25160746 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. Hall MJ; Adin CA; Borin-Crivellenti S; Rudinsky AJ; Rajala-Schultz P; Lakritz J; Gilor C Domest Anim Endocrinol; 2015 Apr; 51():114-21. PubMed ID: 25625650 [TBL] [Abstract][Full Text] [Related]
25. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology. Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS Obesity (Silver Spring); 2019 Dec; 27(12):2005-2010. PubMed ID: 31746553 [TBL] [Abstract][Full Text] [Related]
26. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Flint A; Kapitza C; Hindsberger C; Zdravkovic M Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616 [TBL] [Abstract][Full Text] [Related]
27. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Raun K; von Voss P; Knudsen LB Obesity (Silver Spring); 2007 Jul; 15(7):1710-6. PubMed ID: 17636089 [TBL] [Abstract][Full Text] [Related]
28. Ghrelin levels after a cold pressor stress test in obese women with binge eating disorder. Gluck ME; Yahav E; Hashim SA; Geliebter A Psychosom Med; 2014 Jan; 76(1):74-9. PubMed ID: 24367126 [TBL] [Abstract][Full Text] [Related]
29. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673 [TBL] [Abstract][Full Text] [Related]
31. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Montanya E; Sesti G Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994 [TBL] [Abstract][Full Text] [Related]
32. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial. Soto-Molina H; Pizarro-Castellanos M; Rosado-Pérez J; Rizzoli-Córdoba A; Lara-Padilla E; del Valle-Laisequilla CF; Reyes-García JG Int J Clin Pharmacol Ther; 2015 Jul; 53(7):541-9. PubMed ID: 26073353 [TBL] [Abstract][Full Text] [Related]
33. Relationships among tonic and episodic aspects of motivation to eat, gut peptides, and weight before and after bariatric surgery. Bryant EJ; King NA; Falkén Y; Hellström PM; Holst JJ; Blundell JE; Näslund E Surg Obes Relat Dis; 2013; 9(5):802-8. PubMed ID: 23260807 [TBL] [Abstract][Full Text] [Related]
34. The functional exercise capacity and its correlates in obese treatment-seeking people with binge eating disorder: an exploratory study. Vancampfort D; De Herdt A; Vanderlinden J; Lannoo M; Adriaens A; De Hert M; Stubbs B; Soundy A; Probst M Disabil Rehabil; 2015; 37(9):777-82. PubMed ID: 25030711 [TBL] [Abstract][Full Text] [Related]
35. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099 [TBL] [Abstract][Full Text] [Related]
36. Treatment of binge eating disorder. Wilson GT Psychiatr Clin North Am; 2011 Dec; 34(4):773-83. PubMed ID: 22098803 [TBL] [Abstract][Full Text] [Related]
37. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. Madsen AN; Hansen G; Paulsen SJ; Lykkegaard K; Tang-Christensen M; Hansen HS; Levin BE; Larsen PJ; Knudsen LB; Fosgerau K; Vrang N J Endocrinol; 2010 Sep; 206(3):287-96. PubMed ID: 20508079 [TBL] [Abstract][Full Text] [Related]
38. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. Mansur RB; Ahmed J; Cha DS; Woldeyohannes HO; Subramaniapillai M; Lovshin J; Lee JG; Lee JH; Brietzke E; Reininghaus EZ; Sim K; Vinberg M; Rasgon N; Hajek T; McIntyre RS J Affect Disord; 2017 Jan; 207():114-120. PubMed ID: 27721184 [TBL] [Abstract][Full Text] [Related]
39. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. de Luis DA; Gonzalez Sagrado M; Conde R; Aller R; Izaola O Ann Nutr Metab; 2007; 51(2):134-8. PubMed ID: 17536190 [TBL] [Abstract][Full Text] [Related]
40. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]